We have synthesized a prodrug of the angiotensin-converting enzyme (ACE) inhibitor captopril by coupling this drug covalently to the low molecular weight protein (LMWP) lysozyme. Such drug-LMWP conjugates can be used for renal drug delivery, since LMWPs accumulate specifically in the proximal tubular cells of the kidney. In the present study, we compared the effects of captopril-lysozyme and free captopril in male Wistar rats. ACE activity in plasma and the kidney was measured after intravenous bolus injection of either the captoprillysozyme conjugate (33 mg ⅐ kg Ϫ1 , corresponding to 0.2 mg ⅐ kg Ϫ1 captopril) or equivalent dosages of free captopril and lysozyme. The administration of the captopril-lysozyme conjugate resulted in less plasma ACE inhibition and a longer-lasting renal ACE inhibition compared with the free drug. Effects on blood pressure and natriuresis were studied during intravenous infusion of captopril-lysozyme (275 mg ⅐ kg Ϫ1
blood pressure and natriuresis were studied during intravenous infusion of captopril-lysozyme (275 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 conjugate, corresponding to 5 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 captopril) or an equimolar dosage of free captopril. Captopril-lysozyme did not affect systemic blood pressure, whereas free captopril lowered blood pressure significantly (Ϫ23 Ϯ 32% versus control after 6 h). Captopril-lysozyme increased natriuresis about 3-fold compared with control levels (260 Ϯ 32% after 6 h), whereas free captopril treatment resulted in a reduced sodium excretion (26 Ϯ 12%). Furthermore, captopril at a lower dose, which only moderately lowered blood pressure, showed an increased sodium excretion. We conclude that renal delivery of captopril using captopril-lysozyme results in reduced systemic activity and increased kidney-specific activity of the targeted drug.
In past years, angiotensin-converting enzyme (ACE) inhibitors have been used in the treatment of hypertension and congestive heart failure. Furthermore, ACE inhibitors reduce urinary protein excretion in renal disease and exert a longterm renoprotective effect (Ritz et al., 2000; Taal and Brenner, 2000) , despite the incomplete antiproteinuric effect that only reaches an average of approximately 50% (Lees et al., 1990) . Both systemic and local ACE inhibition are likely to contribute to the beneficial effect of ACE inhibitors, although their relative contributions remain an object of study (Anderson, 1997; Zimmerman and Dunham, 1997; Fogo, 2001) . Drug targeting of an ACE inhibitor to the kidney can be an interesting approach to gain insight into the role of the local ACE in renal (patho)physiology. The renal delivery of an ACE inhibitor will ensure an optimal inhibition of ACE in the kidney, in the absence of actions of the drug elsewhere in the body. In addition, this may increase the therapeutic effectiveness by allowing higher drug dosages, which could be beneficial for normotensive nephrotic subjects, in particular, because in these patients the maximal tolerated dose is limited by the antihypertensive response (Fogo, 2001) .
We have developed a technique for the intrarenal delivery of drugs, using low molecular weight proteins (LMWPs) as drug carriers (Franssen et al., 1994; Haas et al., 1996 Haas et al., , 2001 Haverdings et al., 2001b) . By accumulation in the proximal tubular cells, and subsequent degradation of the carrier, the drug is released site-specifically in the kidney. Previously, we synthesized a conjugate of the ACE inhibitor captopril and the LMWP lysozyme and demonstrated that the captopril-lysozyme conjugate accumulated in the kidney (Kok et al., 1999) . The aim of the present study is to investigate whether captoprillysozyme inhibits renal ACE activity more efficiently and selectively than free captopril. The renal selectivity of ACE inhibition was determined by comparing the renal and plasma ACE inhibition following equivalent doses of the conjugate or free captopril and lysozyme, both administered as intravenous bolus injections. Furthermore, we investigated the effects of continuous infusion of either captopril-lysozyme, captopril, or lysozyme on systemic blood pressure and urinary sodium excretion in unrestrained rats.
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Materials and Methods

Synthesis and Characterization of the Captopril-Lysozyme
Conjugate. The synthesis and characterization of the captoprillysozyme conjugate have been reported previously (Kok et al., 1999) . Briefly, lysozyme (100 mg, 7 mol; Sigma-Aldrich, St. Louis, MO) was dissolved in a 0.1 N borate buffer, pH 7.5, at a concentration of 20 mg ⅐ ml
Ϫ1
. The coupling reagent succinimidyloxycarbonyl-␣-methyl-␣-(2-pyridyldithio)toluene (5.4 mg, 14 mol; Pierce, Rockford, IL) was dissolved in 0.1 ml of acetonitrile and added dropwise to the lysozyme solution. After stirring for 30 min, captopril (3.3 mg, 15 mol; Sigma-Aldrich), dissolved in 0.1 ml of ethanol, was added dropwise to the lysozyme-succinimidyloxycarbonyl-␣-methyl-␣-(2-pyridyldithio)toluene mixture. The reaction mixture was stirred for another 2 h, after which the conjugate was purified by cation exchange chromatography (Hitrap SP Sepharose; Amersham Biosciences, Roosendaal, The Netherlands) using a linear NaCl gradient in 0.1 N borate buffer, pH 7.5. The purified conjugate was dialyzed to water, freeze-dried, and stored at Ϫ20°C until further use. The captopril content of the conjugate was determined by HPLC analysis (Kok et al., 1997) . The conjugates used in this study did not contain unconjugated captopril and had an average captopril/lysozyme coupling degree of 0.4 and 1.2 (mol/mol ratio) for the ACE activity study and continuous infusion experiments, respectively. Animal Experiments. Upon arrival, male Wistar rats (250 -275 g; Harlan, Zeist, The Netherlands) were housed in a temperaturecontrolled room with a 12-h light/dark cycle and were offered ad libitum intake of tap water and a low-sodium diet (0.05% NaCl; HopeFarms, Inc., Woerden, The Netherlands). Injection solutions of administered compounds were prepared in glucose 5% (NPBI, Emmer-kompascuum, The Netherlands).
Effects on Systemic and Renal ACE Activity. Four groups of animals were studied after intravenous bolus injection of 500 l of one of the following treatments: 1) control group (glucose 5%; n ϭ 6 for each time point); 2) lysozyme group (33 mg ⅐ kg Ϫ1 ; n ϭ 3); 3) captopril-lysozyme group (33 mg ⅐ kg
, corresponding to 0.2 mg ⅐ kg Ϫ1 captopril; n ϭ 4 for all time points); and 4) captopril group (0.2 mg ⅐ kg Ϫ1 plus lysozyme 33 mg ⅐ kg
; n ϭ 4 for all time points). Medication was administered via the dorsal penile vein under halothane anesthesia (2% halothane in 2:1 O 2 /N 2 O; 1 liter ⅐ min Ϫ1 ). Except for the first time points (0 and 7.5 min), the rats were allowed to recover from the anesthesia, placed back into their cages, and reanesthetized 5 min before the sampling time point. At the indicated time point, a blood sample was taken via the abdominal vena cava, after which the circulatory system was flushed carefully with a 0.9% saline solution, followed by extirpation of the kidneys. Blood samples were heparinized and centrifuged (5 min at 13,000 rpm) to obtain plasma. The kidney capsule was dissected, and plasma and kidney samples were snap-frozen and stored in liquid nitrogen until further processing as described below.
Measurement of ACE Activity. To prevent loss of ACE inhibition due to oxidation of captopril, ACE activities were determined immediately after the end of the animal experiment, and samples were kept frozen in liquid nitrogen. A 1:5 homogenate of the kidneys was prepared in ice-cold potassium phosphate buffer (pH 7.4) by homogenization for 2 min using an Ultra Turrax T25 homogenizer (IKA, Staufen, Germany). The kidney homogenates were refrozen in liquid nitrogen. ACE activity was measured by the conversion of the ACE substrate Hip-His-Leu (Sigma-Aldrich) to hippurate as described in detail elsewhere (Koiter et al., 1998) . In short, the assay was performed by incubation of 100 l of kidney homogenate at 37°C with the substrate in a potassium phosphate buffer (pH 8.3) for 15 min. The formed hippurate was measured by HPLC. ACE activities were calculated as the nanomoles of hippurate per minute per milliliter (units per milliliters of plasma) or nanomoles of hippurate per minute per kidney weight (units per grams of kidney). In vitro ACE inhibition curves were prepared by spiking freshly prepared plasma and kidney homogenate with appropriate amounts of captopril or captopril-lysozyme, after which the samples were analyzed as described above.
Effects on Systemic Blood Pressure and Natriuresis. To eliminate the effects of animal handling or anesthesia on blood pressure regulation, the effect of captopril-lysozyme and captopril on blood pressure and natriuresis was studied in unrestrained conscious rats as previously described (de Vries et al., 1997) . One week prior to the experiments, the carotid artery and jugular vein were catheterized under halothane anesthesia (2% halothane in 2:1 O 2 / N 2 O, 1 liter ⅐ min Ϫ1 ) for blood pressure measurement and administration of medication, respectively. During the experiments, rats were housed in individual metabolic cages and deprived of water and food to avoid the influence of eating and drinking behavior on blood pressure. Blood pressure was monitored constantly during continuous intra-arterial vehicle infusion (1 ml ⅐ h Ϫ1 glucose 5% containing 2.5 U ⅐ ml Ϫ1 heparin; Leo Pharmaceuticals, Weesp, The Netherlands) using a pressure transducer (Uniflow; Baxter, Irvine, CA) and a recording system (Hewlett Packard 7758B system; Hewlett Packard, Palo Alto, CA). After an equilibration and baseline period of 2 h each, medication was administered via continuous intravenous infusion for 6 h via the jugular catheter. Five groups of animals were studied (n ϭ 6 for all groups): 1) vehicle (glucose 5%); 2) lysozyme (100 mg ⅐ kg
). Vehicle and medication were administered intravenously at a flow rate of 1 ml ⅐ h Ϫ1 using Terufusion syringe pumps (model STC521; Terumo, Tokyo, Japan). Urine samples collected during the experiment were pooled into 2-h periods and analyzed for sodium content by atomic absorption spectrophotometry (PerkinElmer atomic absorbance spectrophotometer 7070B; PerkinElmer, Nieuwerkerk a/d IJssel, The Netherlands).
Calculations and Statistics. The ACE inhibition at selected time points after captopril or conjugate treatment was calculated by dividing the obtained ACE activities by the ACE activity found in the control group at t ϭ 0 min. The renal selectivity was calculated as the ratio of renal ACE inhibition and plasma ACE inhibition.
Baseline systemic blood pressure was determined from the average of 2 h of vehicle infusion. During the 6-h treatment period, blood pressure was calculated as the average of a 10-min period around the selected time points and expressed as the percentile change of baseline values. Individual baseline parameters were calculated for each animal and used to calculate the changes in systolic blood pressure after 2, 4, and 6 h of treatment.
Sodium excretion rates were calculated from the determined sodium concentrations and volumes of the urine fractions for each 2-h period after the start of the infusions. The statistical significance of differences was tested at a significance level of P Ͻ 0.05 using the two-sided Student's t test.
Results
Effects on Plasma and Renal ACE Activity. We studied the ACE-inhibitory effects of captopril-lysozyme or free captopril plus lysozyme in time by measuring the ACE activity in plasma and the kidney. We determined the plasma and renal ACE activity of vehicle-treated control rats and rats that had been injected with lysozyme to investigate a possible effect of anesthesia or the carrier molecule (Fig. 1 ). This figure shows that plasma and renal ACE activity remained rather constant in time, whereas administration of lysozyme was shown to be without any effect on ACE activity.
The effect of captopril-lysozyme and of captopril plus lysozyme on plasma and renal ACE is shown in Fig. 2 . Whereas unconjugated captopril inhibited the plasma ACE significantly at all time points except at 120 min, captopril-lysozyme treatment affected plasma ACE only at the first two time points (7.5 and 15 min). In contrast, captopril-lysozyme displayed a prolonged renal ACE inhibition compared with the free drug; both treatments resulted in significant renal ACE inhibition at all time points. However, free captopril ACE inhibition decreased gradually toward the end of the experiment, whereas captopril-lysozyme ACE inhibition did not. To determine the renal selectivity index (RSI) of the two treatments, we calculated the ratio from plasma and renal ACE inhibition (Fig. 3) . From 30 min onwards, the conjugated captopril showed an 8-fold increased renal selectivity compared with free captopril. Figure 4 shows the ACE inhibition curves of freshly prepared plasma and kidney homogenate samples that had been spiked with captopril or the conjugate. In plasma, free captopril and captopril-lysozyme conjugate showed a 42-fold difference in IC 50 (326 nM and 14 M for captopril and captopril-lysozyme, respectively). For renal ACE, the IC 50 values differed 29-fold (573 nM and 17 M for captopril and captopril-lysozyme, respectively). Assuming that the ACE inhibition of the conjugate results from captopril that has been released from the conjugate after spiking of the samples, the found differences in IC 50 accounted for a free captopril release of approximately 2 and 3% in plasma and kidney homogenate, respectively.
Effects on Systemic Blood Pressure and Natriuresis. We studied the effects of captopril-lysozyme on systemic blood pressure and natriuresis to evaluate whether the observed effects of the conjugate on plasma ACE activity would also lead to other, more physiological effects. To allow optimal administration of a therapeutically appropriate dose of the conjugate, medication was administered by continuous intravenous infusion (Haverdings et al., 2001a) . Baseline Ϫ1 conjugate corresponding to 0.2 mg ⅐ kg Ϫ1 captopril); solid bars, captopril plus lysozyme (0.2 mg ⅐ kg Ϫ1 captopril ϩ 33 mg ⅐ kg Ϫ1 lysozyme). Panel A, plasma ACE inhibition; panel B, renal ACE inhibition (mean Ϯ S.E.M.). ૺ, significant difference between captopril-lysozyme conjugate and captopril ϩ lysozyme (P Ͻ 0.05). Plasma ACE inhibition after captopril-lysozyme treatment was significant versus control at 7.5 and 15 min, and after captopril ϩ lysozyme at 7.5 to 60 min; renal ACE inhibition was significant versus control at all time points in both groups. 
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at ASPET Journals on July 13, 2017 jpet.aspetjournals.org systemic blood pressure of 121 Ϯ 3 mm Hg was comparable for all treatment groups. Infusion of captopril-lysozyme, equimolar to 5 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 captopril, did not affect blood pressure (Fig. 5) . In contrast, 5 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 free captopril resulted in a significant reduction of blood pressure (Ϫ23 Ϯ 2% relative to the vehicle group after 6 h of treatment). Systemic blood pressure remained unchanged during lysozyme infusion and showed a minor reduction after treatment with 1 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 free captopril (data not shown). Throughout the total experimental period, urinary sodium excretion remained constant in the vehicle group but showed remarkable changes after infusion of either conjugate or free captopril (Fig. 6) . Treatment with captopril-lysozyme conjugate resulted in increased sodium excretion, whereas free captopril reduced the excretion of sodium in the urine (Fig.  6) . Compared with control levels at the start of the infusion, natriuresis increased to 260 Ϯ 32% and 26 Ϯ 12% of baseline values after 6 h of infusion of captopril-lysozyme or captopril, respectively. In contrast to the reduced natriuresis after 5 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 captopril, treatment with captopril at a lower dose of 1 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 moderately increased natriuresis (137 Ϯ 7% of baseline values), whereas infusion of lysozyme showed only minor effects on natriuresis (data not shown).
Discussion
Drug-lysozyme conjugates can be used to increase the accumulation of drugs in the kidney. Previously, we demonstrated that captopril-lysozyme can effectuate a 6-fold increased accumulation of captopril in the kidney in comparison with free captopril (Kok et al., 1999) . In the present study, we investigated whether the captopril-lysozyme conjugate could also effectively lower renal ACE activity and induce kidney-specific effects, such as natriuresis. In addition, we investigated plasma ACE inhibition and blood pressure as parameters reflecting systemic, i.e., extrarenal, activity of the conjugate. Our data show an increased renal selectivity of the coupled drug.
The reduced extrarenal activity of captopril-lysozyme emerges from conjugating the thiol moiety of captopril to lysozyme. Since this group is essential for the ACE-inhibitinging capacity of captopril (Ondetti and Cushman, 1981) , the conjugate is an inactive prodrug. Active captopril can be regenerated from the conjugate by incubation with reduced glutathione and other thiol compounds. Consequently, the 40-fold decreased IC 50 produced by conjugation of captopril to the LMWP compared with uncoupled captopril should be interpreted as the release of approximately 2 to 3% free captopril from the conjugate in vitro, rather than an intrinsic ACE-inhibitory effect of captopril-lysozyme. Release of captopril from the conjugate also occurs in vivo, both in the circulation and in the kidney. Yet, ACE inhibitions after administration of conjugate were much higher in the kidney than in plasma, probably due to the rapid accumulation of conjugate in the kidney and the presence of high concentrations of reduced glutathione that can release the coupled drug in the proximal tubular cells (Commandeur and Vermeulen, 1990 ). Previously, we reported that captopril-lysozyme circulated as the intact conjugate in the blood stream, since no free captopril could be detected by HPLC analysis of plasma samples (Kok et al., 1999) . The present data show that the conjugate gives rise to at least some plasma ACE inhibition, which means that free captopril must be present in the circulation. Either this free drug has been released from the carrier prior to accumulation of the conjugate in the kidney, or it has been released from the proximal tubular cells back into the circulation.
Our data on the ACE-inhibitory capacity of free captopril show a rapid but not complete inhibition of plasma and renal ACE. An almost complete plasma and renal ACE inhibition could be reached with a higher dosage of free captopril (0.5 mg ⅐ kg Ϫ1 , data not shown). The renal selectivity of free captopril in this study ranged between 0.8 and 2.1, which indicates a slight accumulation of captopril in the kidney. This is in agreement with previous observations and is likely due to the efficient excretion of captopril by both glomerular . Sodium excretion in urine after 6 h of intravenous treatment. ϫ, vehicle (glucose 5%); f, captopril-lysozyme 275 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 (corresponding to 5 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 captopril); E, captopril 5 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 . ૺ, significant difference versus vehicle (P Ͻ 0.05).
filtration and tubular secretion (Kubo and Cody, 1985; Cushman et al., 1989) . Since the conjugate displayed less plasma ACE inhibition but a similar or higher renal ACE inhibition than free captopril, the RSI of the conjugate was increased at all time points (significant from t ϭ 15 min). This increase in RSI was prominent, in particular, from 30 min after administration and resulted in an 8-fold increase in the renal selectivity index at t ϭ 30 and 60 min.
To determine whether the altered balance between plasma and renal ACE inhibition influences the pharmacological activity of the conjugated captopril, we monitored systemic blood pressure and urinary sodium excretion during intravenous infusion of the conjugate or free captopril. In a previous study, we demonstrated that this slow continuous infusion allows for the administration of high doses of lysozyme without affecting systemic and renal physiology (Haverdings et al., 2001a) . As expected from the literature, intravenous infusion of free captopril resulted in an acute lowering of systemic blood pressure (Cushman et al., 1989 ). However, despite the high dosage of captopril-lysozyme that was administered during this experiment, no effect on systemic blood pressure was observed after infusion of the conjugate. Apparently, the moderate systemic ACE inhibition after infusion of conjugate did not result in changes in the reninangiotensin system that could not be compensated by other blood pressure-regulating mechanisms. From this, we conclude that captopril-lysozyme has reduced systemic activity compared with the free drug. On the other hand, captoprillysozyme infusion resulted in a dramatically increased urinary sodium excretion, which was not observed after infusion of the free drug. Free captopril caused a moderate increase in sodium excretion at low dosage and a decreased natriuresis at equimolar captopril dosage. Since local infusion of captopril in the renal artery increased sodium excretion in unilaterally nephrectomized Wistar rats, we expected an increase in sodium excretion in our experiments after administration of free captopril (Zhang et al., 1995) . Furthermore, changes in systemic blood pressure will influence renal hemodynamics and sodium reabsorption, which can explain the observed reduction in natriuresis after 5 mg ⅐ kg Ϫ1 ⅐ 6 h Ϫ1 free captopril. Thus, the effect of captopril-lysozyme on natriuresis can be regarded as an increased renal efficacy of captopril due to the targeting of the drug.
In conclusion, we have demonstrated that the renal delivery of captopril using the LMWP lysozyme as a kidneyspecific drug carrier results in an increased renal selectivity of the targeted drug with respect to ACE inhibition. Consequentially, captopril-lysozyme exerts reduced systemic pharmacological effects and increased renal effects compared with the free drug, as reflected in blood pressure and sodium excretion. Future studies regarding the antiproteinuric effects of the conjugate after long-term treatment should reveal its potential in renoprotective pharmacotherapy.
